The company decided to settle the complaint in order to avoid "lengthy and distracting litigation," but denies any wrongdoing.
Five hundred pharmacies will provide information about pharmacogenetic testing to members who have failed one or more antidepressant treatments.
The investment firm also reduced its price target to $30 per share from $37 citing "lower overall conviction" that Myriad would meet its revenue projections.
Authors concluded that all three assays — Oncotype DX, EndoPredict, and Prosigna — met Canadian thresholds for cost-effectiveness and urged caution in considering the findings.
The drug is for first-line maintenance therapy after BRCA-mutated advanced ovarian cancer patients respond to platinum chemo and the test will identify those with BRCA mutations.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
Individual stocks in the GenomeWeb Index were mostly down in May, with 21 of the 30 stocks posting losses and nine stocks recording gains.
Olaparib maintenance therapy stretched out progression-free survival, suggesting a need for germline BRCA1/2 mutation testing in pancreatic cancer patients.
The firm reported total revenues of $216.6 million in Q3 2019 compared to $183.1 million a year ago, but it fell short of the consensus Wall Street estimate was $217.5 million.
The firm is seeking approval of myChoice HRD as a test that can identify ovarian, fallopian, or peritoneal cancer patients deficient in homologous recombination DNA repair.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.